SEC filing summary
Filing identity: The supplied filing is Cara Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2014, signed August 7, 2014. This does not match the request metadata identifying Tvardi Therapeutics, Inc.; confirm the intended company and filing before relying on this summary.
Business context and reporting period
Cara was a clinical-stage biopharmaceutical company developing CR845 candidates for pain and pruritus by targeting kappa opioid receptors. It had no products for sale; revenue principally came from licensing and collaboration arrangements. The filing compares the three and six months ended June 30, 2014 with the corresponding 2013 periods. Amounts below are in U.S. dollars; financial statement amounts are shown in millions unless noted.
Financial performance and position
| Metric | Q2 2014 | Q2 2013 | Six months 2014 | Six months 2013 |
|---|---|---|---|---|
| Revenue | $0.96 | $9.97 | $1.14 | $9.97 |
| Research and development expense | $3.20 | $2.02 | $5.40 | $2.94 |
| General and administrative expense | $1.47 | $1.03 | $2.87 | $1.62 |
| Net income (loss) | $(3.65) | $5.34 | $(7.03) | $2.71 |
| Basic net income (loss) per share | $(0.16) | $0.34 | $(0.37) | $0.24 |
- Revenue fell sharply because Cara recognized $9.6 million of Maruishi upfront license consideration in 2013. 2014 revenue included a $0.3 million license milestone and collaboration revenue from deferred license consideration and clinical compound sales.
- Operating loss was $3.7 million in Q2 2014 and $7.1 million for the first half, compared with operating income of $6.9 million and $5.4 million, respectively, in 2013. The filing reports no product-sales gross margin; it is not meaningful for this pre-commercial business.
- At June 30, 2014, cash and cash equivalents were $62.8 million, total assets $68.2 million, current liabilities $5.6 million, and accumulated deficit $69.5 million. The company reported no outstanding convertible preferred stock and no debt balance; prior convertible notes had been converted or repaid.
- Six-month operating cash flow was $(7.3) million, investing cash flow $(0.006) million, and financing cash flow $57.8 million. Cash increased by $50.5 million, primarily reflecting the February 2014 IPO. The IPO raised $63.25 million gross; the filing reports approximately $56.2 million net of underwriting discounts and offering expenses.
- Contractual obligations totaled $7.3 million, principally operating leases and executive employment agreements. Restricted cash was $0.7 million. No off-balance-sheet arrangements were reported.
Material changes versus the prior comparable period
- Lower licensing revenue drove the shift from reported net income in first-half 2013 to a first-half 2014 net loss, while R&D spending rose $2.5 million to $5.4 million as clinical and preclinical work expanded.
- Cash increased from $12.4 million at December 31, 2013 to $62.8 million at June 30, 2014 following the IPO. Common shares outstanding increased from 4.3 million to 22.6 million, including conversion of preferred stock and issuance of IPO shares.
- Interest expense recorded in 2013 largely reflected non-cash charges on convertible notes; in 2014, the company recorded modest interest income after the notes were resolved.
Outlook, management commentary, risks and contingencies
- Management expected June 30 cash to fund operations for at least 18 months, excluding potential collaboration milestone receipts. It expected continued losses, increasing expenses, and no near-term product revenue; runway depends on clinical timing and spending assumptions.
- Management planned to request an FDA End-of-Phase-2 meeting in the second half of 2014 and anticipated starting Phase 3 trials of I.V. CR845 in early 2015, subject to completion of manufacturing and chemistry requirements. A human abuse-liability study began in July 2014, with top-line data expected in Q4 2014.
- The company reported initiating a Phase 1 tablet-formulation study of Oral CR845 in June 2014, with top-line data expected in Q4 2014. It also reported filing an investigational new drug application in June and initiating an I.V. CR845 Phase 2 uremic-pruritus study in August 2014, after the quarter; top-line data were expected in the first half of 2015.
- Maruishi owed a $0.5 million milestone following completion of a Phase 1 trial in Japan. The company recognized $0.3 million as license revenue, recognized a portion as collaboration revenue, and deferred the remainder; the $0.48 million net receivable is reported on the balance sheet. Further Maruishi and CKD milestones and royalties are contingent and uncertain.
- Key risks include clinical-trial success and timing, regulatory approval, manufacturing, intellectual-property protection, competition, commercialization and reimbursement, reliance on collaborators and third parties, and the possibility that additional capital may be needed. Management said disclosure controls were effective and reported no material legal proceedings or new risk factors.
Important facts for investors to verify
- Confirm that Cara Therapeutics’ 2014 second-quarter filing, rather than a Tvardi Therapeutics filing, is the intended source.
- Check subsequent FDA and clinical-trial milestones against the stated plans, including Phase 3 timing and expected study readouts.
- Review cash burn and runway against actual trial spending, and confirm the timing and collection of the Maruishi milestone receivable.
- Assess the impact of future financing or equity awards on dilution; the filing reports 1.06 million options outstanding at June 30, 2014.
- Consider the one-time 2013 licensing revenue when comparing reported revenue and earnings across periods.